TCAI and St. David’s Medical Center Advance Cardiac Rhythm Innovation
Austin, Texas, USA — May 22, 2026 The Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center has...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Austin, Texas, USA — May 22, 2026 The Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center has...
WHIPPANY, N.J., May 21, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
SAN CLEMENTE, Calif., May 20, 2026 Reflow Medical, Inc. has announced encouraging six-month clinical results from its DEEPER CORONARY...
